INTERNATIONAL JOURNAL OF PHARMA PROFESSIONAL'S RESEARCH



"FORMULATION AND EVALUATION OF TRANSDERMAL PATCH OF AMLODIPIN BESYLATE"

Priyanka Yadav *, Dharmendra Solanki, Anjali Soni, Ritu Jaiswal

Lakshmi Narain College of Pharmacy, Indore, MP, 453555

Keywords:
Transdermal patch, Bioavailability, TDDS, Skin, Controlled release, Amlodipin besylate

Corresponding Author-
Ms. Priyanka Yadav
Contact no- 7999063524
Email ID-
priyayadav2902@gmail.com

ABSTRACT:

A Transdermal patch is a medicated adhesive patch that is placed on the skin to deliver a distinct dose of medication through the skin and into the blood stream. The transdermal drug delivery system is one of novel drug delivery system which overcomes arise from the traditional dosage form. The preformulation studies involves description, solubility, melting point of the drug were found to be comparable with the standard. Based on the preformulation studies the drug was suitable for making the transdermal formulation. In this transdermal drug delivery system F5 was having greater % drug release. The formulation F5 shows better extended release up to 24hrs when compared to other formulations. So it was concluded that the formulation F5 prepared by using Eudragit RS100 and HPMC is the better formulation for control release of drug up to 24hrs of time. However, the best formulation F-5 follows first order kinetics and the mechanism of diffusion. Results of the present study encouraged that it can be used as controlled drug delivery system and frequency of administration can be minimized.

Introduction:

Transdermal drug delivery system (TDDS) established itself as an integral part of novel drug delivery system. Transdermal patches are polymeric formulation which when applied to skin deliver the drug at a predetermined rates across dermis to achieve systemic effect[1]. Transdermal dosage form, though a costly alternative to conventional formulations, are becoming popular because of their unique advantages. Controlled absorption, more uniform plasma levels, improved bioavailability, reduced side effect, painless, ease of application and flexibility of terminating drug administration by simply removing the patch from the skin are some of the potential advantages of transdermal drug delivery. Development of controlled release transdermal dosage form is a complex process involving extensive efforts[2] .

Transdermal drug delivery can closely mimic the slow intravenous infusion, without its potential hazards and also offer another most important advantages in allowing the patient to terminate the drug therapy by

simply removing the patch at any desired time if toxicity develops[3].

MATERIALS AND METHODS

I. MATERIALS

HPMC/Eudragit RS 100, distilled water, propylene glycol, Amlodipine besylate, Hydroxy propyl methylcellulose, ethaol.

II. EXPERIMENTAL WORK

1) Preformulation Studies:

1. **Organoleptic properties of drug:** A small quantity of drug sample was taken on butter paper and viewed in well illuminated place. It results as it's shown as white powder. Very less quantity of drug was used to get taste as well as smelled to get the odor. It is bitter in taste and odorless.

2. **Determination of solubility:** A qualitative determination of the solubility was made by adding solvent in small incremental amount to a test tube containing fixed quantity of solute and vice versa. After each addition, the system
3. is vigorously shaken and observed visually. It is slightly soluble in distilled water and partially soluble in Methanol, Ethanol and Methylene Chloride.

4. **Determination of melting point**
   Melting point of Amlodipine besylate was determined by using capillary method. In this method little amount of Amlodipine besylate was filled in capillary after that the capillary was tied to a thermometer with the help of a rubber band. The thermometer with capillary was placed into Theil's tube which was previously filled with paraffin oil. The paraffin oil in the tube was heated until the drug melts. The temperature at which drug begins to melt was recorded. The specified melting point is 190-200℃ and the observed melting point is 192-196℃.

5. **Partition Coefficient**
   A partition coefficient (P) or distribution coefficient (D) is the ratio of concentrations of a compound in a mixture of two immiscible solvents at equilibrium. Partition coefficient are useful in estimating the distribution of drugs within the body. The specified partition coefficient is 2.70 and the observed partition coefficient is 2.66.

6. **Quantitative estimation of drug by Calibration Curve method.**

2) Calibration of Phosphate buffer pH 7.4

Various dilutions were prepared to get concentrations 2, 4, 6, 8, 10, 12, 14, 16, 18, 20 µg/ml. The graph of concentration v/s absorbance was plotted and data was subjected to linear regression analysis.

S. No.	Concentration (µg/ml)	Absorbance
1	2	0.054
2	4	0.121
3	6	0.192
4	8	0.255
5	10	0.321

Table No. 1 Calibration curve of Amlodipine besylate in phosphate buffer saline pH 7.4 (λmax 238nm)



Fig. No. 1 Calibration curve of in Amlodipine Besylate in phosphate buffer saline pH 7.4

3) UV spectroscopic studies

The maximum wavelength of Amlodipine besylate was found to be 245 nm which matches the reported wavelength.

S.No.	Solvent	Peak Point Observed	Peak Point specified
1	Phosphate Buffer pH 7.4	245 nm	230-250 nm

Table No. 2 UV spectroscopic studies of Amlodipine Besylate



Fig no. 2 UV Spectra of Amlodipine Besylate sample in Phosphate buffer saline pH 7.4

FORMULATION AND EVALUTION OF TRANSDERMAL PATCH OF AMLODIPINE BESYLATE:

The Transdermal patch were prepared by solvent casting method. The different concentration of polymer (Eudragit RS 100 and HPMC) were weighed and used in suitable solvent of ethnol 20ml and known volume of PG (Propylene Glycol). As an Permeation enhancer PEG- 400 (polyethylgycol)was used in the preparation.

PROCEDURE

Transdermal patch of Amlodipine besylate was prepared by solvent casting method. The polymer (for example HPMC/Eudragit RS 100) was taken in a beaker with a minimum quantity of the solvent. Then 2/3rd of the solvent was mixed with the polymers and was added firstly with stirring at lower rpm and later at a higher speed. The plasticizer was added and homogeneously mixed, the drug was included with enduring agitation and the volume was made up. The patches were cast onto a suitably designed and fabricated glass mould and then dried in oven at 40°C. The patches were removed by using sharp blade by inserting along the edges of the patch. The dried patches were wrapped in butter paper and stored in a closed container away from light and in cool place.

RESULT

1 Drug content determination

From all the optimized patches, the formulation of batch F5 was highest drug content.

S.NO.	Formulation	Drug Content
1	F1	93.43%
2	F2	93.90%
3	F3	90.00%
4	F4	95%
5	F5	95.62%
6	F6	92.32%

Table No. 3. Drug Content

2 Percentage Cumulative Drug Release of Formulation F1 to F6, n=6

S. NO.	Time	FORMULATION					
		F1	F2	F3	F4	F5	F6
1	0	0.0 ±0.00	0.0± 0.0	0.0± 0.0	0.0±0.00	0.0± 0.0	0.0± 0.0
2	1	1.0± 0.15	3.8± 0.36	0.0± 0.0	3.5±0.21	5.0± 0.10	7.3± 0.61
3	2	1.3± 0.15	6.7± 0.25	7.7± 0.30	5.4±0.40	5.5± 0.50	8.8± 0.54
4	3	2.0± 0.26	8.8± 0.41	14.5 ±0.25	7.4±0.31	7.4± 0.48	10.8 ±0.43
5	4	6.2± 0.25	11.4 ±0.40	15.6 ±0.40	7.8±0.34	10.2 ±0.26	13.6 ±0.12
6	5	6.7± 0.36	13.4 ±0.15	16.3 ±0.26	8.3±0.56	11.4 ±0.22	14.2 ±0.65
7	6	7.6± 0.30	15.4 ±0.47	17.6 ±0.10	10.1± 0.10	13.7 ±0.48	17.0 ±0.68

8	7	9.0± 0.25	19.2 ±0.4 5	21.4 ±0.3 2	11.3± 0.75	15.6 ±0.3 8	18.7 ±0.2 0
9	8	11.1 ±0.3 5	21.0 ±0.2 0	23.6 ±0.3 5	13.4± 0.86	19.9 ±0.6 7	20.7 ±0.1 7
10	9	12.8 ±0.4 0	21.8 ±0.3 5	26.1 ±0.5 5	14.9± 0.62	24.1 ±0.3 6	21.8 ±0.3 5
11	10	15.2 ±0.4 5	25.3 ±0.5 0	27.9 ±0.4 0	16.0± 0.28	33.0 ±0.1 5	26.5 ±0.3 0
12	11	18.1 ±0.4 0	27.7 ±0.3 0	29.6 ±0.6 8	16.7± 0.15	33.8 ±0.1 0	28.0 ±0.2 2
13	12	21.4 ±0.7 5	35.4 ±0.9 2	31.9 ±0.4 5	21.4± 0.12	37.3 ±0.6 7	28.5 ±0.1 5
14	24	61.4 ±0.4 5	56.4 ±0.7 5	51.8 ±0.5 0	24.1± 0.76	69.3 ±0.7 8	58.4 ±0.9 0

Table No. 4 % CDR of Formulation F1, F2, F3,F4,F5,F6



Fig.No. 3 Percentage Cumulative Drug Release

Based on all these factors the transdermal drug delivery system F5 is having greater % drug release. The formulation F5 shows better extended release up to 24hrs when compared to other formulations. So it was concluded that the formulation F5 prepared by using Eudragit RS100 and HPMC is the better formulation for control release of drug up to 24hrs of time.

S. NO.	Batch No.	Evaluation Parameters	Results
1	F5	Thickness	0.23+0.01
2	F5	Weight variation	230±0.3
3	F5	Moisture Content	4.39 ± 0.04
4	F5	Moisture Uptake	4.02±0.06
5	F5	Folding Endurance	24.1±1.52

8 *In-vitro* Drug Release Studies

S. No.	Time (hrs)	Absorbance
1	**0**	**0.00±0.0**
2	**1**	**5.0±0.1**
3	**2**	**5.5±0.5**
4	**3**	**7.4±0.48**
5	**4**	**10.2±0.26**
6	**5**	**11.4±0.22**
7	**6**	**13.7±0.48**
8	**7**	**15.6±0.38**
9	**8**	**19.9±0.67**
10	**9**	**24.1±0.36**
11	**10**	**33.0±0.15**
12	**11**	**33.8±0.10**
13	**12**	**37.3±0.67**
14	**24**	**69.3±0.78**

Table No. 5 Drug release studies of Optimized Batch F5

CONCLCONCLUSION

Transdermal route is convenient, safe and offers several potential advantages over conventional routes like avoidance of first pass metabolism, predictable and extended duration of action, minimizing undesirable side effects, utility of short half-life drugs, improving physiological and pharmacological response, avoiding the fluctuation in drug levels, inter and intra-patient variations and most importantly, it provides patient compliance as the drug delivery is painless. Transdermal therapeutic systems are defined as self-contained, discrete dosage forms which, when applied to the intact skin, deliver the drug(s), through the skin, at a controlled rate to the systemic circulation. The preparation and evaluation of transdermal patches of Amlodipine besylate with a view to develop controlled release formulation with two polymers namely HPMC & Eudragit RS100. The transdermal patch were formulated by using solvent evaporation technique. The patches obtained were of uniform weight and thickness indicating the well distribution of the drug in the polymeric solution. The moisture content uptake values were small indicating the prepared patches were stable and the prepared

formulation can be used for the transdermal application.

Conficts of Interest : No conflicts of interest to reveal.

Funding statements : No funding.

REFERENCES

1) A, Karki N, Charde R, Charde M, Ganghare B "Transdermal drug delivery system: an Ahmed overview" International Journal of Biomed Advance Research, (2011), 38-56.
2) Arunachalam A, Kartikayam N, Kumar VD, Prathap M, Sethuraman S, Ashutosh kumar S, Manidipa S " Transdermal drug delivery system" Current Pharma Research, (2012), 1(1), 70-81.
3) Ashok KJ, Pullakandam N, Lakshmana PS, Gopal V " Transdermal drug delivery system" (2010), (3), 49-50.
4) Arora Ritika, Aggrawal Geeta, S.L. Harikumar, Kirandeep Kaur "Nanoemulsion Based Hydrogel for Enhanced Transdermal Delivery of Ketoprofen" Advances in Pharmaceutics Article ID (2014), 468456, 12.
5) Aranaz I, Mengibar M (2009) "Functional Characterization of Chitin and Chitosan" Current Chemical Biology, (2009), 3, 203-23.
6) Bharkatiya M, Nema N.K, Bhatnagar M (2010) "Designing and Characterization of Drug Free Patches for Transdermal Application" International Journal of Pharmaceutical Science and Drug Research, (2010), 2(1), 35-39.
7) Brown MB, Martin GP, Jones SA "Dermal and transdermal drug delivery systems: current and future prospects: Drug Delivery" (2010), 13, 175–187.
8) Davis SP, Martanto W, Alen MG, Prausnitz MR "Hollow metal microneedles for insulin delivery to diabetic rats" Biomeed Engg, (2005), (52), 109-115
9) Dhiman, S., T.G. Singh, and A.K. Rehni "Transdermal patches: A recent approch to new drug delivery system" Int J Pharm Pharm Sci, (2011), 3(5), 26-34.
10) Das A, Sibaji G, Biiplab KR, Daeyal K "A Novel Technique for Treating the Type-II Diabetes by Transdermal Patches Prepared by using Multiple Polymer Complex" International Journal of Research and Development, (2010), 2(1), 27.
11) Eseldin K, Sharma R.K, Mosa B "Transdermal Patch- A Review" International Journal of Advance in Pharmaceutical Science, (2010), 1(2), 201-211.
12) El-Kattan AF, Asbil CS, Michniak BB "The Effect of Terpene Enhancer Lipophilicity on the Percutaneous Permeation of Hydrocortisone Formulated in HPMC Gel Systems" International Journal of Pharmacy, (2000), 179–189.
13) Amin S, Mir SR, Kohli K, Ali A "Novel Polymeric Matrix Film for Transdermal Delivery of Metoclopromide" International Journal Pharma Front Research, (2012), 2(1), 48-60.
14) E. Abraham theodore, barish, dr. R. Manavalan, adithi viswanath, dr. R. Venkatanarayanan (2016) "Research on formulation and evaluation of transdermal patches of amlodipine besylate" World journal of pharmacy and pharmaceutical sciences, volume (2016), 5, (3) 1302-1314.
15) Guy RH "Current status and future prospects of transdermal drug delivery" Pharm Research, (1996), (13), 1765-1769.
16) Ghosh TK, "Transdermal drug delivery system" International Pharmacy Press, (2002), 22(6), 39.
17) Jain A, Ghosh B, Nayak S " A Study of Transdermal Delivery of Glibenclamide Using Iontophoresis" International Journal of Health Research, (2009), 2(1), 83-91.
18) Jain SK, Gupta SP " Effective and controlled transdermal delivery of Metaprolol Tartarate" Indian Journal Pharm Science, (2009), (67), 376-50.
19) Johnson ME, Mitragotri S, Patel A, Blankschtein D, Langer R " Synergistic effect of ultrasound and chemical enhancers on transdermal drug delivery" J Pharm Science, (1996), 85.
20) Kaur M, Popova IE "Microneedle-assisted delivery of verapamil hydrochloride and amlodipine besylate" Eur J Pharm Biopharm, (2014), 86, 284–291.
21) Kydoneius AF "Fundamental of transdermal drug delivery" CRC Press. Boca Raton Florida, (1987), 31.
22) Kashmira Kathe, Harsha Kathpalia "Film forming systems for topical and transdermal drug delivery", Asian journal of pharmaceutical sciences, (2017), 10, 1016.
23) Kaynak MS, Bogacz A, Stelmasinski M "Bioavailability file: amlodipine" Fabad J Pharm Sci., (2011), 36, 207–222.
24) Kavita K, Mangesh R "Design and Evaluation of Transdermal Film of Lornoxicam" International Journal of Pharma and Bio Sciences, (2011), 2(2), 54.

25) Loyd V. Allen, Nicholas G. Popovich, Howard C. Ansel Pharmaceutical dosage forms and drug delivery systems, 8th Edition., Wolter Kluwer Publishers,New Delhi, 2005, 298-299.

26) Manda Pruthvi Raj, Mokalla Niharika "Formulation and characterization of transdermal patches of amlodipine besylate using olive oil as the natural permeation enhancer" Indo American Journal of Pharmaceutical Research, (2016), (6)6, 5723.

27) Manvi FV, Dandagi PM "Formulation of transdermal drug delivery system of ketotifen fumarate" Indian Journal Pharma Science, (2003), 65(3), 10-11.

28) Minghetti P "Development of Local Patches Containing Melilot Extract and Ex Vivo–In Vivo Evaluation of Skin Permeation" Europe Journal Pharm Science, (2000), (10) 111–117.

29) Mayorga, P"Research Note Rodent malaria prophylaxis by transdermal delivery of primaquine" International journal for parasitology, . (1998), 28(8), 1283-1285

30) Narsimha MS, Hamsa V "Comparative release studies of transdermal films of terbutaline sulphate across various diffusion barriers" Indian Journal Pharm Science, (1996), 196-201.

31) Nishant Thakur, Payal Mittal, Pradeep Goyal, Manish Goswami, Ritika Puri, Kritika Sharma "Recent Advances in the Formulation of Transdermal System with Reference to the Polymers and Permeation Enhancers" A Review, Int. J. Pharm. Sci. Rev. Res., (2017), 46(2), 149-154.

32) Pavan Kumar Yadav, Saurabh Mishra "Transdermal patch of an antihypertensive drug: its Development and evaluation" World journal of pharmaceutical research, (2017), (6)4, 1335-1374.